Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Citizens Commission on Human Rights International Los AngelesCoroner Finds Multiple Psychiatric Drugs in Mother-Daughter Murder-Suicide; Citizens Commission on Human Rights International Calls for Violence Cases to Undergo Same TestsGroup cites 12 deaths in five 2026 attacks and urges states to require psychiatric-drug toxicology in homicides and mass acts of senseless violence
- Verastem OncologyVerastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerBOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
- Acadia Pharmaceuticals Inc.Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No.
- Attovia Therapeutics, Inc.Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.
- Definium Therapeutics, Inc.Definium Therapeutics Announces New Employee Inducement GrantsNEW YORK, September 28, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of Septembe
- Meitheal Pharmaceuticals, Inc.Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®CHICAGO, September 28, 2026--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced that the U.S. Food and Drug Administration ("FDA") has approved a high-concentration formulation ("HCF") for YUSIMRY® (adalimumab-aqvh), as an interchangeable biosimilar to Humira®.
- GENFIT Reports First-Half 2026 Financial Results and Provides Corporate UpdateLille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.
- INSTYTUTUMINSTYTUTUM Clinical Study Shows a Three-Year Reduction in Calculated Skin Biological Age in 84 DaysSwiss longevity skincare brand reveals new clinical data supporting a new approach to skin health, biological aging and skinspan — INSTYTUTUM, the Swiss longevity skincare brand founded by longevity scientist and biotech innovator Dr. Natalia Bobok,...
- Kuehn Law, PLLCKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential...
- Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)Company announcement No. 50 / 2026
- Powerful NeOnc Brain Cancer Pipeline AdvancesNeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
- Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer StudyOncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.